ABSTRACT
The aim of this study was to assess the relation between benign endometrial pathologies (polyp and/or hyperplasia without atypia) and the metabolic status (insulin resistance and metabolic syndrome) of the patients. A total of 168 cases were enrolled in the study. The patients were classified according to the presence of benign endometrial pathologies and their menopausal status. Then, the subjects were evaluated according to the metabolic syndrome criteria and the presence of an insulin resistance. The insulin resistance levels of the cases were analysed by four different methods. Obesity and a waist circumference of greater than 88 cm were observed significantly more in the study group with endometrial pathologies (p = .005 and p < .001, respectively). It was also observed that a fasting blood glucose level of higher than 110 mg/dL increased the risk of developing endometrial polyps and/or hyperplasia without atypia by almost five folds (OR: 5.26, 95% CI: 1.25-22.12). Furthermore, an insulin resistance was found to be significantly high in the study group (p = .002). Based on the observed significant relationship between an insulin resistance and benign endometrial pathologies, it can be concluded that insulin resistance plays an important role in the development of benign endometrial pathologies. Impact Statement What is already known on this subject? Metabolic anomalies such as obesity, type 2 diabetes, hypertension and dyslipidaemia play an important role in abnormal endometrial proliferation. Also, these metabolic anomalies have been known as risk factors for type I endometrial cancer. What the results of this study add? A significant relationship between an insulin resistance and benign endometrial pathologies was observed. What the implications are of these findings for clinical practice and/or further research? Based on this finding, we concluded that an insulin resistance may play an important role in the development of benign endometrial pathologies. The prevention and the treatment of obesity as a key factor of developing an insulin resistance, may reduce not only the incidence of malignant endometrial pathologies, but also the incidence of benign pathologies and of a malignant transformation.
